Aromasin
Aromasin (Exemestane 25 mg) — Pfizer steroidal aromatase inhibitor for HR+ post-menopausal breast cancer. Irreversible aromatase inactivator with distinct profile from non-steroidal AIs.
✓ Medicinskt granskad av Morgan Ellis — Apoteksforskare · 8 års erfarenhet · Senast granskad: maj 2026
Quick Answer
Aromasin — Exemestane 25 mg (Pfizer). Aromatase inhibitor for hormone-receptor-positive (HR+) breast cancer in post-menopausal women — adjuvant, extended adjuvant, and metastatic settings. Once-daily oral.
Vad du får med MedsBase:
- WHO-GMP-certifierad tillverkare
- Diskret förpackning i vanligt kuvert
- Världsvid leverans
- Betygsatt av 1 400+ kunder (läs recensioner)
📦 Reshipment Assurance: om din order inte har anlänt 20 arbetsdagar efter försändelse, skickar vi en ny utan extra kostnad. Läs policyn.
Varför beställa från MedsBase
Aromasin ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
AIs are NOT effective in pre-menopausal women — without ovarian suppression, ovaries override AI inhibition. Pre-menopausal HR+ breast cancer requires tamoxifen ± ovarian suppression (LHRH agonist) or AI WITH ovarian suppression as a specialist-supervised regimen.
AIs accelerate bone density loss and fracture risk. Baseline DEXA is recommended; consider bisphosphonate (zoledronic acid, ibandronate) or denosumab in osteopenia/osteoporosis. AIs may modestly raise lipid levels and cardiovascular events vs tamoxifen. Monitor lipids and cardiovascular risk factors annually.
Vanliga frågor
AI vs tamoxifen — which is better?
In post-menopausal HR+ breast cancer, AIs (anastrozole, letrozole, exemestane) give modestly higher disease-free survival than tamoxifen (ATAC, BIG 1-98, MA.17). AIs are preferred adjuvant in most post-menopausal women; tamoxifen remains preferred in pre-menopausal disease and in patients with severe AI side effects.
How long is treatment?
Adjuvant therapy is typically 5 years; some women benefit from extended adjuvant (5-10 years total) based on ATLAS/MA.17 data. Specialist decides extended therapy based on recurrence risk.
Common side effects?
Hot flushes, joint and muscle pain (arthralgia/myalgia — affects 30-50%, often improves with continued therapy), fatigue, vaginal dryness, mood changes, accelerated bone loss.
Joint pain — is it serious?
AI-related arthralgia is the most common reason for non-adherence. Often improves over 3-6 months; symptomatic relief with NSAIDs, exercise, occasionally switching between AIs (anastrozole ↔ letrozole ↔ exemestane). Vitamin D + calcium adequacy helps.
What if I’m pre-menopausal?
AIs alone do not work — ovaries override. Discuss tamoxifen, or AI + ovarian suppression, with your specialist.
Benmineralhalt?
Mandatory baseline DEXA. Repeat every 1-2 years. Add a bisphosphonate or denosumab if osteopenia or osteoporosis develops, or in high baseline-risk patients prophylactically.
Side effects vs exemestane?
Anastrozole and letrozole are non-steroidal AIs (reversible). Exemestane is a steroidal AI (irreversible inactivator). Side-effect profiles broadly similar; some women prefer one over another. Switching is reasonable for tolerability.
Vaginal dryness?
Common. Topical vaginal moisturisers and water-based lubricants help. Topical oestrogen (very low dose, vaginal) is generally avoided in HR+ breast cancer; if symptoms severe, discuss with oncologist — vaginal DHEA, ospemifene, or specialist menopause review may be options.
Läkemedelsinteraktioner?
Few major. CYP-modulators have minimal effect on AIs. Tamoxifen and AIs should NOT be combined (no benefit). Always disclose all medications.
Vad händer om jag missar en dos?
Take when you remember if same day; otherwise skip. Do not double up. Consistent daily dosing maximises effect.
Other Cancer & Hormonal Therapy Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia
More options in Anti Cancer Medication
Rangerade efter senaste ordervolym på MedsBase — vad andra kunder i denna kategori väljer.
| Styrka | 25 mg |
|---|---|
| Kvantitet | 15 Tablet/s, 30 Tablet/s, 60 Tablet/s |
| Farmaceutisk form | Tabletter |
| Tillverkare | Pfizer Ltd |
| Behandling | Breast cancer |
| Generiskt märke | Exemestane |
Aromasin
Frågor & svar
Aromasin
Relaterade produkter
Recensioner
Det finns inga recensioner än